These genomic distinctions play a crucial role in shaping the propensity for metastasis in each GC subtype.[28–30] CDH1 mutation is the most frequent genetic alteration which is highly associated with early-onset diffuse GC.[31] A previous study unveiled that intestinal-type GC and late-onset patients were often linked with a high frequency of TP53 mutations, predisposing them to liver metastasis. This evidence concerns the gene CDH1 and gastric cancer.